FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068525079> ?p ?o ?g. }

• W2068525079 endingPage "1169" @default.
• W2068525079 startingPage "1164" @default.
• W2068525079 abstract "Objective To investigate the association between age-related macular degeneration (AMD) and exposure to antacids, antithyroids, thyroid hormones, and thiazide diuretics. Design Matched case–control study. Participants Population-based participants were selected from the United Kingdom General Practice Research Database. A total of 18 007 people with diagnosed AMD were compared with 86 169 controls matched for age, gender, and general practice. Methods Conditional logistic regression was used to determine the association between exposure to each drug group of interest and a diagnosis of AMD, adjusting for relevant confounding variables. Main Outcome Measures The primary outcome was the odds ratio for the association between exposure to antacids, antithyroids, thyroid hormones, or thiazide diuretics and AMD. Secondary analyses were conducted to assess the effect of recent exposure to the drugs of interest, the total number of prescriptions received, and restricting the data set to participants with more than 2 years of observation time. Results The crude odds ratios for association between any record of drug exposure and AMD were as follows: 1.34 (95% confidence interval [CI], 1.29–1.39) for antacids; 1.15 (95% CI, 0.92–1.44) for antithyroids; 1.34 (95% CI, 1.29–1.39) for thyroid hormones; and 1.13 (95% CI, 1.08–1.17) for thiazide diuretics. After adjusting for consultation rate, observation time, diabetes, heart failure, hyperlipidemia, cardiovascular drug use, atherosclerosis, hypertension, aspirin use, hormone replacement therapy use, body mass index, alcohol consumption, and smoking, the odds ratios reduced to: 1.06 (95% CI, 1.02–1.10) for antacids, 0.98 (95% CI, 0.78–1.24) for antithyroids, 0.99 (95% CI, 0.92–1.06) for thyroid hormones, and 0.98 (95% CI, 0.94–1.02) for thiazides. Secondary analyses were consistent with these findings for all 4 drug categories. Conclusions No association was detected between short- and medium-term use of antithyroids, thyroid hormones, and thiazide diuretics and the risk of AMD. Short- and medium-term use of antacids seems to be associated with a small increase in the risk of this disease. However, this increased risk is likely the result of residual confounding by smoking or uncontrolled confounding resulting from socioeconomic status. No conclusions could be drawn regarding longer-term use of each drug category. To investigate the association between age-related macular degeneration (AMD) and exposure to antacids, antithyroids, thyroid hormones, and thiazide diuretics. Matched case–control study. Population-based participants were selected from the United Kingdom General Practice Research Database. A total of 18 007 people with diagnosed AMD were compared with 86 169 controls matched for age, gender, and general practice. Conditional logistic regression was used to determine the association between exposure to each drug group of interest and a diagnosis of AMD, adjusting for relevant confounding variables. The primary outcome was the odds ratio for the association between exposure to antacids, antithyroids, thyroid hormones, or thiazide diuretics and AMD. Secondary analyses were conducted to assess the effect of recent exposure to the drugs of interest, the total number of prescriptions received, and restricting the data set to participants with more than 2 years of observation time. The crude odds ratios for association between any record of drug exposure and AMD were as follows: 1.34 (95% confidence interval [CI], 1.29–1.39) for antacids; 1.15 (95% CI, 0.92–1.44) for antithyroids; 1.34 (95% CI, 1.29–1.39) for thyroid hormones; and 1.13 (95% CI, 1.08–1.17) for thiazide diuretics. After adjusting for consultation rate, observation time, diabetes, heart failure, hyperlipidemia, cardiovascular drug use, atherosclerosis, hypertension, aspirin use, hormone replacement therapy use, body mass index, alcohol consumption, and smoking, the odds ratios reduced to: 1.06 (95% CI, 1.02–1.10) for antacids, 0.98 (95% CI, 0.78–1.24) for antithyroids, 0.99 (95% CI, 0.92–1.06) for thyroid hormones, and 0.98 (95% CI, 0.94–1.02) for thiazides. Secondary analyses were consistent with these findings for all 4 drug categories. No association was detected between short- and medium-term use of antithyroids, thyroid hormones, and thiazide diuretics and the risk of AMD. Short- and medium-term use of antacids seems to be associated with a small increase in the risk of this disease. However, this increased risk is likely the result of residual confounding by smoking or uncontrolled confounding resulting from socioeconomic status. No conclusions could be drawn regarding longer-term use of each drug category." @default.
• W2068525079 created "2016-06-24" @default.
• W2068525079 creator A5006378101 @default.
• W2068525079 creator A5019521414 @default.
• W2068525079 creator A5022288501 @default.
• W2068525079 creator A5053553303 @default.
• W2068525079 creator A5063172840 @default.
• W2068525079 creator A5069614553 @default.
• W2068525079 date "2007-06-01" @default.
• W2068525079 modified "2023-09-23" @default.
• W2068525079 title "A Case–Control Study of Drug Risk Factors for Age-Related Macular Degeneration" @default.
• W2068525079 cites W1560237148 @default.
• W2068525079 cites W1576497894 @default.
• W2068525079 cites W1691887444 @default.
• W2068525079 cites W1780202576 @default.
• W2068525079 cites W1941964179 @default.
• W2068525079 cites W1965038445 @default.
• W2068525079 cites W1975032911 @default.
• W2068525079 cites W1976951345 @default.
• W2068525079 cites W1990217299 @default.
• W2068525079 cites W2010982408 @default.
• W2068525079 cites W2032879794 @default.
• W2068525079 cites W2062577694 @default.
• W2068525079 cites W2073741050 @default.
• W2068525079 cites W2092369059 @default.
• W2068525079 cites W2102446763 @default.
• W2068525079 cites W2133158775 @default.
• W2068525079 cites W2141960190 @default.
• W2068525079 cites W2147440920 @default.
• W2068525079 cites W2157604999 @default.
• W2068525079 cites W2159767143 @default.
• W2068525079 cites W2166175175 @default.
• W2068525079 cites W2598520882 @default.
• W2068525079 cites W4230439113 @default.
• W2068525079 cites W4236626209 @default.
• W2068525079 cites W4244094502 @default.
• W2068525079 cites W4248715188 @default.
• W2068525079 doi "https://doi.org/10.1016/j.ophtha.2006.09.018" @default.
• W2068525079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17544775" @default.
• W2068525079 hasPublicationYear "2007" @default.
• W2068525079 type Work @default.
• W2068525079 sameAs 2068525079 @default.
• W2068525079 citedByCount "29" @default.
• W2068525079 countsByYear W20685250792012 @default.
• W2068525079 countsByYear W20685250792013 @default.
• W2068525079 countsByYear W20685250792014 @default.
• W2068525079 countsByYear W20685250792015 @default.
• W2068525079 countsByYear W20685250792016 @default.
• W2068525079 countsByYear W20685250792017 @default.
• W2068525079 countsByYear W20685250792019 @default.
• W2068525079 countsByYear W20685250792020 @default.
• W2068525079 countsByYear W20685250792021 @default.
• W2068525079 countsByYear W20685250792022 @default.
• W2068525079 crossrefType "journal-article" @default.
• W2068525079 hasAuthorship W2068525079A5006378101 @default.
• W2068525079 hasAuthorship W2068525079A5019521414 @default.
• W2068525079 hasAuthorship W2068525079A5022288501 @default.
• W2068525079 hasAuthorship W2068525079A5053553303 @default.
• W2068525079 hasAuthorship W2068525079A5063172840 @default.
• W2068525079 hasAuthorship W2068525079A5069614553 @default.
• W2068525079 hasConcept C118487528 @default.
• W2068525079 hasConcept C126322002 @default.
• W2068525079 hasConcept C134018914 @default.
• W2068525079 hasConcept C146304588 @default.
• W2068525079 hasConcept C156957248 @default.
• W2068525079 hasConcept C2776403814 @default.
• W2068525079 hasConcept C2780221984 @default.
• W2068525079 hasConcept C2780437262 @default.
• W2068525079 hasConcept C2908647359 @default.
• W2068525079 hasConcept C44249647 @default.
• W2068525079 hasConcept C555293320 @default.
• W2068525079 hasConcept C71924100 @default.
• W2068525079 hasConcept C84393581 @default.
• W2068525079 hasConcept C99454951 @default.
• W2068525079 hasConceptScore W2068525079C118487528 @default.
• W2068525079 hasConceptScore W2068525079C126322002 @default.
• W2068525079 hasConceptScore W2068525079C134018914 @default.
• W2068525079 hasConceptScore W2068525079C146304588 @default.
• W2068525079 hasConceptScore W2068525079C156957248 @default.
• W2068525079 hasConceptScore W2068525079C2776403814 @default.
• W2068525079 hasConceptScore W2068525079C2780221984 @default.
• W2068525079 hasConceptScore W2068525079C2780437262 @default.
• W2068525079 hasConceptScore W2068525079C2908647359 @default.
• W2068525079 hasConceptScore W2068525079C44249647 @default.
• W2068525079 hasConceptScore W2068525079C555293320 @default.
• W2068525079 hasConceptScore W2068525079C71924100 @default.
• W2068525079 hasConceptScore W2068525079C84393581 @default.
• W2068525079 hasConceptScore W2068525079C99454951 @default.
• W2068525079 hasIssue "6" @default.
• W2068525079 hasLocation W20685250791 @default.
• W2068525079 hasLocation W20685250792 @default.
• W2068525079 hasOpenAccess W2068525079 @default.
• W2068525079 hasPrimaryLocation W20685250791 @default.
• W2068525079 hasRelatedWork W1925385967 @default.
• W2068525079 hasRelatedWork W2115595203 @default.
• W2068525079 hasRelatedWork W2312874961 @default.
• W2068525079 hasRelatedWork W2321021262 @default.
• W2068525079 hasRelatedWork W2468724271 @default.

• next